MediWound is a biotechnology specialty company of global, innovative
products addressing unmet-needs in the fields of burn and wound
Removal of the burn’s dead tissue (eschar) is a crucial step in preventing
infections and preparing the cleaned wound for spontaneous healing
or grafting. Currently, eschar removal involves prolonged non-surgical
treatment or traumatic, surgical procedures which involve the loss of
blood and healthy tissue.
MediWound develops and produces Debrase, the first-line product for
selective and prompt eschar removal, establishing a minimal invasive
modality for burn care. Fulfilling the unmet-need for effective, selective
and fast eschar removal, Debrase has been granted an orphan-drug
status in Europe and the US.
Debrase is a sterile mixture of proteolytic enzymes derived from
the pineapple plant stem. Presented in more than 70 international
meetings and 3 peer-reviewed papers, it is in a multinational (4
continents) Phase 3 study involving hundreds of patients.
Typically applied for 4 hours, Debrase effectively and selectively
removes the eschar, enabling accurate diagnosis and treatment
within hours of hospital admission. It leaves the viable tissues intact,
maximizing spontaneous healing and minimizing patient trauma and
surgery (eschar excision, grafting and graft harvesting from healthy
donor skin). Debrase prevents and rapidly resolves Burn Induced
Compartment Syndrome which endangers blood circulation and
may result in limb amputation, thus replacing the current solution of
traumatic and dangerous surgical escharotomy. Debrase is applied
at the patient’s bedside without need for operation rooms, anesthesia
and surgical stuff.
Watch movie >>